Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: Dave Gore who wrote (17383)	5/13/1998 1:56:00 PM
From: Leman	Read Replies (1) \| Respond to of 34592

HYALF info Actinic Keratosis, caused by sun damage to the skin, can be the first warning of the potential to develop skin cancer. With approximately 4 million treatments annually, actinic keratosis represents a $240 million market in the U.S. alone. Hyal has completed its clinical development of Solarase and is in the process of filing for regulatory approval in a number of major jurisdictions. Solarase is licensed to F.H. Faulding for the territories of Australia, New Zealand, Singapore and Malaysia and to Adcock Ingram for southern Africa. Hyal is in discussions with a number of multi-national pharmaceutical companies who are interested in licensing Solarase elsewhere in the world.